Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

85.04
-1.4900-1.72%
Post-market: 85.040.00000.00%17:09 EDT
Volume:1.48M
Turnover:126.09M
Market Cap:16.61B
PE:19.47
High:87.00
Open:87.00
Low:84.90
Close:86.53
52wk High:87.24
52wk Low:53.56
Shares:195.28M
Float Shares:163.04M
Volume Ratio:0.91
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.37
EPS(LYR):0.1575
ROE:24.30%
ROA:11.52%
PB:3.98
PE(LYR):540.02

Loading ...

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Aug 23

Incyte Is Maintained at Neutral by JP Morgan

Dow Jones
·
Aug 22

Incyte price target raised to $73 from $67 at JPMorgan

TIPRANKS
·
Aug 22

JPMorgan Adjusts Price Target on Incyte to $73 From $67, Maintains Neutral Rating

MT Newswires Live
·
Aug 22

U.S. RESEARCH ROUNDUP-Heico, Nordson, Workday

Reuters
·
Aug 22

Qiagen NV Releases Transcript for Second Quarter 2025 Results Call

Reuters
·
Aug 22

Incyte’s Latest Study on INCB086550: Key Insights for Investors

TIPRANKS
·
Aug 22

Cytokinetics Appoints Jim Daly to Board of Directors, Enhancing Commercial Expertise

Reuters
·
Aug 20

Sheila A. Denton, EVP & General Counsel, Reports Disposal of Incyte Corporation Common Shares

Reuters
·
Aug 20

Incyte Corporation to Present at Upcoming Investor Conferences in September

Reuters
·
Aug 19

Incyte Corp. Stock Slides 2.3%, Underperforms Competitors

Dow Jones
·
Aug 19

Cancer Stock Soars While This China Tech Stock Heads To New Highs

Blockhead
·
Aug 16

Incyte’s Rollover Study: A New Chapter for Povorcitinib

TIPRANKS
·
Aug 16

Incyte’s Axatilimab Study: A Potential Game-Changer for cGVHD Treatment

TIPRANKS
·
Aug 16

Harrow Stock Eyes Relative Strength Rating Upgrade

Blockhead
·
Aug 15

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Aug 12

Incyte’s Phase 1 Study on INCB086550: A Potential Breakthrough in Cancer Treatment

TIPRANKS
·
Aug 12

Incyte’s Phase 3 Study on Povorcitinib: A Potential Game-Changer for Prurigo Nodularis

TIPRANKS
·
Aug 09

Incyte’s Rollover Study on Povorcitinib: Key Insights for Investors

TIPRANKS
·
Aug 09

Merus NV Reports Q2 2025 Revenue Increase of $1.5 Million, Driven by Higher Collaboration Sales

Reuters
·
Aug 08